In Europe and the US, semaglutide is approved to treat obesity and type 2 diabetes
Appetite suppression remains
Eli Lilly, which makes Mounjaro, warns that gallstones may affect up to one in 10 people taking the drug for weight loss, listing them as a common side effect in its patient information leaflet
The pharmacokinetic profiles differ in meaningful ways
Unless you have exceptional circumstances (modest weight loss goal, strong lifestyle capacity, history of successful maintenance), assume Retatrutide will be ongoing treatment
Semaglutide storage comparison Semaglutide (Ozempic, Wegovy) follows very similar storage rules to brand-name tirzepatide